For instance, 1 patient with complete regression of treated tumor had a log-fold increase of 0.6 for CD28, 0.6 for lymphocyte activation gene 3 protein, and 0.4 for programmed cell death ligand 1, whereas another patient (with best local response of −17%) had log-fold changes of 0.1, −0.1, and 0, respectively (eFigure 12 in Supplement 2). The gene discussed is CD28; the disease is neoplasm.